-
1 month ago | 
onclive.com | Amer M Zeidan
CommentaryVideoMay 8, 2025Supplements and Featured PublicationsResearch Efforts Seeking to Raise the Bar in Low-Risk MDSVolume1 Issue 1Author(s):Fact checked by:,Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.
-
Feb 7, 2025 | 
onclive.com | Courtney DiNardo |Rami D. Komrokji |Amer M Zeidan
OpinionVideoFebruary 7, 2025Author(s):,Panelists discuss how the future treatment landscape for myelodysplastic syndromes (MDS) appears promising with several ongoing clinical trials exploring novel combinations and targeted therapies, including investigations of venetoclax combinations, magrolimab, sabatolimab, and other immune-based approaches that could potentially improve outcomes across different risk groups and molecular subtypes.
-
Feb 7, 2025 | 
onclive.com | Courtney DiNardo |Rami D. Komrokji |Amer M Zeidan
Opinion Video February 7, 2025 Author(s): , Panelists discuss how treatment strategies for myelodysplastic syndromes (MDS) are fundamentally guided by risk stratification, with lower-risk patients typically receiving supportive care and less intensive treatments focused on quality of life and symptom management while intermediate- to high-risk patients require more aggressive approaches, including hypomethylating agents and consideration for stem cell transplantation, with emerging data...
-
Feb 3, 2025 | 
onclive.com | Amer M Zeidan |Guillermo Garcia-Manero
Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDSAmer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
-
Feb 3, 2025 | 
onclive.com | Amer M Zeidan |Guillermo Garcia-Manero
Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCCDr Levy on the Development and Clinical Use of ADCs in NSCLC
-
Feb 3, 2025 | 
onclive.com | Amer M Zeidan |Guillermo Garcia-Manero
The Potential of Oral HMAs in MDSAmer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
-
Jan 31, 2025 | 
onclive.com | Courtney DiNardo |Rami D. Komrokji |Amer M Zeidan
OpinionVideoJanuary 31, 2025Author(s):,Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup. Video content above is prompted by the following:• Can you share any key takeaways or additional data updates surrounding MDS presented at ASH 2024?
-
Dec 23, 2024 | 
onclive.com | Amer M Zeidan
Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007Dr. Amer Zeidan presents interim Phase 1a results from the KOMET-007 trial, demonstrating the safety and robust clinical activity of ziftomenib combined with intensive chemotherapy (7+3) in newly diagnosed adverse-risk NPM1-mutated and KMT2A-rearranged acute myeloid leukemia, highlighting high response rates and promising survival outcomes.
-
Nov 26, 2024 | 
newswise.com | Amer M Zeidan |George Goshua
Yale Cancer Center to Highlight Breakthroughs in Blood Cancers and Disorders at World’s Largest Hematology Meeting Known as “the premier event in classical and malignant hematology”, the ASH meeting includes oral and poster presentations, as well as workshops and educational sessions for hematology professionals and advocates. Leading YCC hematologist-oncologists will share advances in treating blood cancers and blood disorders. YCC research will cover treatment disparities among older people...
-
Sep 24, 2024 | 
ajmc.com | Ryan Haumschild |James McCloskey |Amer M Zeidan |Zahra Mahmoudjafari |Tracey Iraca
OpinionVideoSeptember 24, 2024Author(s):Medical experts discuss considerations and patient guidance for oral and IV HMAs.Video content above is prompted by the following:What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient preferences?
